NO20054136L - Imidazol-4-yl-etynyl-pyridin-derivater - Google Patents

Imidazol-4-yl-etynyl-pyridin-derivater

Info

Publication number: NO20054136L
Authority: NO; Norway
Prior art keywords: imidazol; pyridine derivatives; ylethynyl; disease; alkyl
Prior art date: 2003-03-10

Application number

NO20054136A

Other languages

English (en)

Norwegian (no)

Other versions

NO20054136D0 (no

Inventor

Sabine Kolczewski

Bernd Buettelmann

Georg Jaeschke

Eric Vieira

Simona Maria Ceccarelli

Richard Hugh Phillip Porter

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-03-10

Filing date

2005-09-06

Publication date

2005-09-26

2005-09-06 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2005-09-06 Publication of NO20054136D0 publication Critical patent/NO20054136D0/no

2005-09-26 Publication of NO20054136L publication Critical patent/NO20054136L/no

Links

DEJSKFIZYYGXSU-UHFFFAOYSA-N 2-ethynyl-3-(1h-imidazol-5-yl)pyridine Chemical class C#CC1=NC=CC=C1C1=CN=CN1 DEJSKFIZYYGXSU-UHFFFAOYSA-N 0.000 title 1
208000024827 Alzheimer disease Diseases 0.000 abstract 2
208000019901 Anxiety disease Diseases 0.000 abstract 1
208000023105 Huntington disease Diseases 0.000 abstract 1
102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 abstract 1
108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 abstract 1
208000018737 Parkinson disease Diseases 0.000 abstract 1
206010039966 Senile dementia Diseases 0.000 abstract 1
230000001154 acute effect Effects 0.000 abstract 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
230000036506 anxiety Effects 0.000 abstract 1
230000001684 chronic effect Effects 0.000 abstract 1
230000003412 degenerative effect Effects 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
206010013663 drug dependence Diseases 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
201000006417 multiple sclerosis Diseases 0.000 abstract 1
210000000653 nervous system Anatomy 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
208000020016 psychiatric disease Diseases 0.000 abstract 1
JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
201000000980 schizophrenia Diseases 0.000 abstract 1
208000011117 substance-related disease Diseases 0.000 abstract 1
230000000472 traumatic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Addiction (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

NO20054136A 2003-03-10 2005-09-06 Imidazol-4-yl-etynyl-pyridin-derivater NO20054136L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP03004952		2003-03-10
PCT/EP2004/002276 WO2004080998A1 (fr)	2003-03-10	2004-03-05	Derives de l'imidazol-4-yl-ethynyl-pyridine

Publications (2)

Publication Number	Publication Date
NO20054136D0 NO20054136D0 (no)	2005-09-06
NO20054136L true NO20054136L (no)	2005-09-26

Family

ID=32981724

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20054136A NO20054136L (no)	2003-03-10	2005-09-06	Imidazol-4-yl-etynyl-pyridin-derivater

Country Status (30)

Country	Link
US (1)	US7153874B2 (fr)
EP (1)	EP1606277B8 (fr)
JP (1)	JP4404896B2 (fr)
KR (1)	KR100742019B1 (fr)
CN (1)	CN100358889C (fr)
AR (1)	AR043501A1 (fr)
AT (1)	ATE395345T1 (fr)
AU (1)	AU2004220382B2 (fr)
BR (1)	BRPI0408093A (fr)
CA (1)	CA2516682C (fr)
CL (1)	CL2004000449A1 (fr)
CO (1)	CO5601027A2 (fr)
DE (1)	DE602004013746D1 (fr)
DK (1)	DK1606277T3 (fr)
ES (1)	ES2305739T3 (fr)
HR (1)	HRP20050774A2 (fr)
IL (1)	IL170129A (fr)
MX (1)	MXPA05009524A (fr)
MY (1)	MY135491A (fr)
NO (1)	NO20054136L (fr)
NZ (1)	NZ541643A (fr)
PA (1)	PA8597301A1 (fr)
PE (1)	PE20041061A1 (fr)
PL (1)	PL1606277T3 (fr)
PT (1)	PT1606277E (fr)
RU (1)	RU2342383C2 (fr)
SI (1)	SI1606277T1 (fr)
TW (1)	TWI292318B (fr)
WO (1)	WO2004080998A1 (fr)
ZA (1)	ZA200506834B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA80888C2 (en) *	2003-06-05	2007-11-12	Hoffmann La Roche	Imidazole derivatives as glutmate receptor antagonists
US7452909B2 (en) *	2003-09-04	2008-11-18	Hoffman-La Roche Inc.	Imidazole derivatives
NZ551253A (en) *	2004-06-01	2010-07-30	Hoffmann La Roche	Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as MGLU5 receptor antagonists
EP1756086B1 (fr) *	2004-06-01	2008-06-04	F.Hoffmann-La Roche Ag	Pyridin-4-yl-ethynyl-imidazoles et pyrazoles, antagonistes du recepteur mglur5
EP2258358A3 (fr)	2005-08-26	2011-09-07	Braincells, Inc.	Neurogenèse avec un inhibiteur de l'acetylcholinestérase
EP2275095A3 (fr)	2005-08-26	2011-08-17	Braincells, Inc.	Neurogenese par modulation des recepteurs muscariniques
EP1940389A2 (fr)	2005-10-21	2008-07-09	Braincells, Inc.	Modulation de la neurogenese par inhibition de la pde
AU2006308889A1 (en)	2005-10-31	2007-05-10	Braincells, Inc.	GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
DE102006011574A1 (de)	2006-03-10	2007-10-31	Grünenthal GmbH	Substituierte Imidazo[2,1-b]thiazol-Verbindungen und ihre Verwendung zur Herstellung von Arzneimitteln
JP2009536667A (ja)	2006-05-09	2009-10-15	ブレインセルス，インコーポレイティド	５ｈｔ受容体介在性の神経新生
EP2382975A3 (fr)	2006-05-09	2012-02-29	Braincells, Inc.	Neurogénèse par modulation d'angiotensine
AU2007292848A1 (en) *	2006-09-08	2008-03-13	Braincells, Inc.	Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
MY148217A (en)	2006-12-21	2013-03-29	Hoffmann La Roche	Polymorphs of a mglur5 receptor antagonist
WO2010099217A1 (fr)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
US8334287B2 (en)	2009-07-17	2012-12-18	Hoffmann-La Roche Inc.	Imidazoles
US8586581B2 (en) *	2009-12-17	2013-11-19	Hoffmann-La Roche Inc	Ethynyl compounds useful for treatment of CNS disorders
HRP20150555T1 (hr)	2011-04-26	2015-07-03	F. Hoffmann - La Roche Ag	Derivati etinila kao pozitivni alosterijski modulatori za mglur5
UA116023C2 (uk)	2013-07-08	2018-01-25	Ф. Хоффманн-Ля Рош Аг	Етинільні похідні як антагоністи метаботропного глутаматного рецептора
EP3400220B1 (fr) *	2016-01-05	2021-03-24	Hua Medicine (Shanghai) Ltd.	Dérivés de pyrazole
UY37556A (es)	2017-01-10	2018-07-31	Bayer Ag	Derivados heterocíclicos como pesticidas
AR113206A1 (es)	2017-01-10	2020-02-19	Bayer Cropscience Ag	Derivados heterocíclicos como pesticidas
EP4069685A1 (fr) *	2019-12-02	2022-10-12	F. Hoffmann-La Roche AG	Inhibiteurs d'alcynyle- (hétéroaryl)-carboxamide hcn1
CN111416154B (zh) *	2020-05-22	2021-08-06	松山湖材料实验室	高电压锂离子电池电解液硅基吡啶添加剂、电解液及其电池
AU2022251771A1 (en)	2021-03-27	2023-09-21	Syngenta Crop Protection Ag	Microbiocidal isonicotinic amide derivatives
WO2023089049A2 (fr)	2021-11-19	2023-05-25	Syngenta Crop Protection Ag	Dérivés d'amide isonicotinique microbiocide
JP2026502124A (ja)	2022-12-19	2026-01-21	シンジェンタクロッププロテクションアクチェンゲゼルシャフト	殺微生物性ピリダジンジヒドロオキサジアジン誘導体

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3303199A (en) *	1963-07-15	1967-02-07	Geigy Chem Corp	Certain imidazolone derivatives and process for making same
US3341548A (en) *	1964-04-29	1967-09-12	Hoffmann La Roche	Nitroimidazoles and their preparation
DE2035905A1 (de)	1970-07-20	1972-02-03	Chemische Fabrik Stockhausen & Cie.,4150Krefeld	Imidazolverbindungen und deren Herstellungsverfahren
CA1174673A (fr)	1981-02-27	1984-09-18	Walter Hunkeler	Imidazodiazepines
US4711962A (en) *	1984-10-18	1987-12-08	Stauffer Chemical Company	Process for selective preparation of ratios of isomers formed on N-substitution of asymmetric imidazoles
US4868181A (en) *	1986-08-04	1989-09-19	E. I. Du Pont De Nemours And Company	1,4-dihydropyridine derivatives with calcium agonist and alpha1 -antagonist activity
US4882343A (en) *	1987-08-28	1989-11-21	G. D. Searle & Co.	Biarylalkylimidazole derivatives as anti-depressants
SG52709A1 (en)	1989-06-30	1998-09-28	Du Pont	Substituted imidazoles
TW544448B (en) *	1997-07-11	2003-08-01	Novartis Ag	Pyridine derivatives
CA2297732C (fr)	1997-08-14	2008-04-29	F. Hoffmann-La Roche Ag	Ethers heterocycliques de vinyle utiles contre des troubles neurologiques
JP4815083B2 (ja)	1999-08-31	2011-11-16	メルク・シャープ・エンド・ドーム・コーポレイション	複素環化合物およびそれの使用方法
WO2002046166A1 (fr)	2000-12-04	2002-06-13	F. Hoffmann-La Roche Ag	Derives phenylethenyle ou phenylethinyle servant d'antagonistes de recepteur de glutamate
WO2003053922A2 (fr) *	2001-12-19	2003-07-03	Merck & Co., Inc.	Imidazoles substitues par heteroaryle modulateurs du recepteur metabotropique du glutamate de type 5

2004
- 2004-03-04 TW TW093105737A patent/TWI292318B/zh not_active IP Right Cessation
- 2004-03-05 JP JP2006504558A patent/JP4404896B2/ja not_active Expired - Fee Related
- 2004-03-05 PL PL04717578T patent/PL1606277T3/pl unknown
- 2004-03-05 BR BRPI0408093-9A patent/BRPI0408093A/pt not_active IP Right Cessation
- 2004-03-05 AT AT04717578T patent/ATE395345T1/de active
- 2004-03-05 DE DE602004013746T patent/DE602004013746D1/de not_active Expired - Lifetime
- 2004-03-05 MX MXPA05009524A patent/MXPA05009524A/es active IP Right Grant
- 2004-03-05 ES ES04717578T patent/ES2305739T3/es not_active Expired - Lifetime
- 2004-03-05 WO PCT/EP2004/002276 patent/WO2004080998A1/fr not_active Ceased
- 2004-03-05 CA CA002516682A patent/CA2516682C/fr not_active Expired - Fee Related
- 2004-03-05 PA PA20048597301A patent/PA8597301A1/es unknown
- 2004-03-05 PT PT04717578T patent/PT1606277E/pt unknown
- 2004-03-05 EP EP04717578A patent/EP1606277B8/fr not_active Expired - Lifetime
- 2004-03-05 CN CNB2004800065725A patent/CN100358889C/zh not_active Expired - Fee Related
- 2004-03-05 HR HR20050774A patent/HRP20050774A2/xx not_active Application Discontinuation
- 2004-03-05 KR KR1020057016753A patent/KR100742019B1/ko not_active Expired - Fee Related
- 2004-03-05 DK DK04717578T patent/DK1606277T3/da active
- 2004-03-05 AU AU2004220382A patent/AU2004220382B2/en not_active Ceased
- 2004-03-05 SI SI200430735T patent/SI1606277T1/sl unknown
- 2004-03-05 RU RU2005131165/04A patent/RU2342383C2/ru not_active IP Right Cessation
- 2004-03-05 NZ NZ541643A patent/NZ541643A/en unknown
- 2004-03-08 CL CL200400449A patent/CL2004000449A1/es unknown
- 2004-03-08 PE PE2004000252A patent/PE20041061A1/es not_active Application Discontinuation
- 2004-03-08 US US10/795,619 patent/US7153874B2/en not_active Expired - Fee Related
- 2004-03-08 AR ARP040100722A patent/AR043501A1/es not_active Application Discontinuation
- 2004-03-09 MY MYPI20040806A patent/MY135491A/en unknown
2005
- 2005-08-04 IL IL170129A patent/IL170129A/en not_active IP Right Cessation
- 2005-08-25 CO CO05085015A patent/CO5601027A2/es active IP Right Grant
- 2005-08-25 ZA ZA200506834A patent/ZA200506834B/en unknown
- 2005-09-06 NO NO20054136A patent/NO20054136L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
IL170129A (en)	2013-02-28
PL1606277T3 (pl)	2008-10-31
MY135491A (en)	2008-04-30
CN1759111A (zh)	2006-04-12
BRPI0408093A (pt)	2006-02-14
KR100742019B1 (ko)	2007-07-23
HK1089443A1 (zh)	2006-12-01
NO20054136D0 (no)	2005-09-06
CL2004000449A1 (es)	2005-01-07
WO2004080998A1 (fr)	2004-09-23
KR20050109074A (ko)	2005-11-17
AU2004220382A1 (en)	2004-09-23
SI1606277T1 (sl)	2008-08-31
AR043501A1 (es)	2005-08-03
EP1606277B1 (fr)	2008-05-14
ZA200506834B (en)	2006-05-31
CA2516682C (fr)	2010-02-02
JP2006519802A (ja)	2006-08-31
ES2305739T3 (es)	2008-11-01
CA2516682A1 (fr)	2004-09-23
RU2342383C2 (ru)	2008-12-27
PE20041061A1 (es)	2005-01-22
TW200423935A (en)	2004-11-16
MXPA05009524A (es)	2005-10-18
JP4404896B2 (ja)	2010-01-27
CN100358889C (zh)	2008-01-02
CO5601027A2 (es)	2006-01-31
DK1606277T3 (da)	2008-08-18
US20040229917A1 (en)	2004-11-18
EP1606277B8 (fr)	2008-10-15
AU2004220382B2 (en)	2007-08-02
HRP20050774A2 (en)	2006-09-30
TWI292318B (en)	2008-01-11
PA8597301A1 (es)	2004-09-16
EP1606277A1 (fr)	2005-12-21
US7153874B2 (en)	2006-12-26
NZ541643A (en)	2008-03-28
DE602004013746D1 (de)	2008-06-26
RU2005131165A (ru)	2007-04-20
ATE395345T1 (de)	2008-05-15
PT1606277E (pt)	2008-07-08

Legal Events

Date	Code	Title	Description
2011-10-24	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20054136L (no)	2005-09-26	Imidazol-4-yl-etynyl-pyridin-derivater
MA27134A1 (fr)	2005-01-03	Derives diarylcycloalkyle, leur procede de preparation et leur utilisation en tant qu'activateurs des ppar
NO20082768L (no)	2008-06-24	Levodopa prodroge mesylat, sammensetninger og anvendelser derav
WO2007127505A3 (fr)	2007-12-27	Composés chimiques
NO20056130L (no)	2006-02-27	Nye substituerte 3-svovelindoler
CY1111206T1 (el)	2015-06-11	Βενζοθειοφαινια υποκατεστημενα με πιπεραζινη για την αγωγη διανοητικων διαταραχων
TNSN06053A1 (en)	2007-10-03	6-substituted anilino purines as rtk inhibitors
NO20062303L (no)	2006-07-19	Pyrazinderivater og farmasoytisk anvendelse derav
CY1110745T1 (el)	2015-06-10	Παραγωγα πυρρολιδονης ως αναστολεις μαοβ
EA200500250A1 (ru)	2005-12-29	Аналоги тиомолибдата и их применение
NO20025517D0 (no)	2002-11-18	Triazolderivater
WO2005123703A3 (fr)	2006-10-12	Nouveauc derives alkynyl servant de modulateurs de recepteurs de glutamate metabotropiques
PL1706113T3 (pl)	2009-07-31	Sposób wytwarzania chlorowodorku 4-(2-dipropyloaminoetylo)-1,3-dihydro-2H-indol-2-onu
ATE402176T1 (de)	2008-08-15	Pyrrolidin- und azetidinverbindungen alsccr5- antagonisten
NO20060328L (no)	2006-02-17	Kombinasjon av mGluR2-antagonist og ACHE-inhibitor for behandiing av akutt og/eller kronisk neurologiske forstyrrelser
DK1578740T3 (da)	2007-07-30	1,2,4-triaminobenzenderivater, der er egnede til behandling af lidelser i centralnervesystemet
DK1272208T3 (da)	2011-10-31	Anvendelse af VEGF 165 og homologer til at behandle neuron-sygdomme
NO20060020L (no)	2006-03-03	3-fluorpiperidiner som NMDA/NR2B-antagonister
WO2007127393A3 (fr)	2008-10-09	Méthodes de traitement et de criblage servant à promouvoir la neurogenèse
WO2008142896A1 (fr)	2008-11-27	Cataplasme et procédé de production de cataplasme
WO2006021000A3 (fr)	2006-06-15	Amides d'acide carboxylique de thienopyrrole substitues, amides d'acide carboxylique de pyrrolothiazole, et analogues apparentes utilises comme inhibiteurs de la caseine kinase i epsilon
WO2022204362A3 (fr)	2022-11-24	Compositions et méthodes de traitement d'un trouble neurodégénératif ou du développement
NO20056116L (no)	2006-02-24	Tiowolframatanaloger og anvendelse av slike
WO2007021575A3 (fr)	2007-04-05	Piperazines acetyleniques servant d'antagonistes a des recepteurs de glutamate metabotropiques
DOP2004000843A (es)	2004-09-15	Derivados de imidazol-4-il-etinil-piridina